6.11
  Price7.19%   +0.41
(Pre-market: .00 -6.11 -100.00%)
May-11-22 01:01AM What 5 Analyst Ratings Have To Say About Kodiak SciencesBenzinga
12:38PM Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in FocusZacks Investment Research
May-06-22 08:50AM Should You Buy Kodiak (KOD) Ahead of Earnings?Zacks Investment Research
Mar-31-22 11:30AM Why Is Kodiak Sciences Inc. (KOD) Down 12.7% Since Last Earnings Report?Zacks Investment Research
Mar-05-22 11:07AM 2 Dirt Cheap Biotechs to Buy If You're a ContrarianThe Motley Fool
Mar-04-22 05:10AM The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon PharmaceuticalsZacks Investment Research
Mar-03-22 10:59AM Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's WhyZacks Investment Research
Mar-02-22 10:11AM Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in FocusZacks Investment Research
08:36AM Why Kodiak Sciences (KOD) Might Surprise This Earnings SeasonZacks Investment Research
Mar-02-22 07:50AM The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With SanofiBenzinga
Feb-25-22 10:00AM Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 WeeksZacks Investment Research
12:25PM Kodiak Sciences: KSI-301 DisappointsSeeking Alpha
Feb-24-22 02:11AM Expert Ratings For Kodiak SciencesBenzinga
07:28AM 10 Biggest Price Target Changes For ThursdayBenzinga
Feb-23-22 04:17AM Why Kodiak Sciences Stock Is Cratering TodayThe Motley Fool
09:01AM Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed WednesdayThe Motley Fool
Feb-23-22 08:01AM The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory DevelopmentBenzinga
07:02AM Why Kodiak Sciences Shares Are Plunging TodayBenzinga
Feb-18-22 11:07AM Executives Buy Around $500M Of 4 StocksBenzinga
Feb-04-22 11:55AM Kodiak (KOD) Completes Enrolling Patients in Retina-Based StudiesZacks Investment Research
Feb-02-22 05:23AM A Peek Into The Markets: US Stock Futures Higher; Alphabet Tops Q4 ViewsBenzinga
Dec-30-21 10:18AM Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301Zacks Investment Research
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Cap:    |  Volume (24h):